Abstracts tagged "fibromyalgia"

Abstract Number: 2048 • 2012 ACR/ARHP Annual Meeting
Four Physician Global Assessments for Overall Status, Inflammation, Damage, and Unexplained Symptoms Are Useful in Usual Care of Patients with Osteoarthritis, Fibromyalgia, Systemic Lupus Erythematosus, and Spondyloarthropathy, As Well As Rheumatoid Arthritis
Isabel Castrejón¹, Martin J. Bergman² and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Taylor Hospital, Ridley Park, PA
Background/Purpose: A physician global estimate (DOCGL) is important in clinical decisions concerning patients with rheumatoid arthritis (RA), and often is the most efficient of the…
Abstract Number: 955 • 2012 ACR/ARHP Annual Meeting
Post – Surgical Outcome Is Correlated with Pre – Surgical Symptoms of Fibromyalgia in Patients Undergoing Spinal Surgery
Jacob N. Ablin¹, Mark Berman², Eyal Behrbalk³, Dan Buskila⁴, Gilad Regev³ and Zvi Lidar³, ¹Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Internal Medicine F, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Department of Neurosurgery and Orthopedic, Department of Neurosurgery and Orthopedic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Chronic pain is a major symptom for which patients undergo spinal surgery. At the same time, chronic pain is considered an entity in and…
Abstract Number: 2030 • 2012 ACR/ARHP Annual Meeting
A Multi-Modal Amplified Musculoskeletal Pain Treatment Program: Associations of Previous Pharmacotherapy with Subsequent Outcomes
Cara M. Hoffart¹, Pamela Weiss², David D. Sherry³, Chris Feudtner⁴ and Margaret Stineman⁵, ¹The Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of General Pediatrics, Children's Hospital of Philadelphia; University of Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, ⁵The University of Pennsylvania, Philadelphia, PA
Background/Purpose: Management of Amplified Musculoskeletal Pain (AMP) in children (i.e. juvenile primary fibromyalgia, complex regional pain syndrome, neuropathic pain, central sensitization) remains controversial. Common practice…
Abstract Number: 957 • 2012 ACR/ARHP Annual Meeting
Key Psychological Processes Associated with the Fibromyalgia Phenotype Exist On a Continuous Spectrum with Asymptomatic People
Katrina Malin¹ and Geoffrey O. Littlejohn², ¹Medicine, Monash University, Clayton, Australia, ²Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia
Background/Purpose: The core features of the fibromyalgia phenotype, the widespread pain and widespread tenderness, represent one extreme of a continuous spectrum with asymptomatic people at…
Abstract Number: 1879 • 2012 ACR/ARHP Annual Meeting
Work Related Injuries Causing or Aggravating Fibromyalgia in the Medicolegal Arena: A Jurisprudential Analysis
Mary-Ann Fitzcharles¹, Peter A. Ste-Marie² and Yoram Shir³, ¹Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Up to 40% of persons report onset of fibromyalgia (FM) following a “triggering event”. Injuries, which may occur in the workplace, may be implicated…
Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting
Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Bruce Daugherty, Leland Gershell and Seth Lederman, Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…
Abstract Number: 1881 • 2012 ACR/ARHP Annual Meeting
Increased Psychosocial Stress Is a Major Component of Fibromyalgia Triggers
Emma K. Guymer¹, Kathleen Elford² and Geoffrey O. Littlejohn³, ¹Rheumatology and Medicine, Monash Medical Centre and Monash University, Clayton, Victoria, Australia, ²Rheumatology, Monash Medical Centre, Clayton, Victoria, Australia, ³Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia
Background/Purpose: Fibromyalgia is a common, chronic pain disorder. Initial development of symptoms occurs under conditions unique to each patient. Psychological and physical triggers are recognized,…
Abstract Number: 963 • 2012 ACR/ARHP Annual Meeting
Efficacy of Long-Term Milnacipran Treatment in Patients Meeting Different Thresholds of Clinically Relevant Pain Relief: Subgroup Analysis of a Double-Blind, Placebo-Controlled Discontinuation Study
Daniel J. Clauw¹, Philip J. Mease², Robert H. Palmer³, Joel M. Trugman⁴ and Yimin Ma⁴, ¹Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: Patients with fibromyalgia (FM) who received up to 3.25 years of milnacipran (MLN) in a flexible-dose (≤200 mg/d) open-label (OL) study were eligible to…
Abstract Number: 1882 • 2012 ACR/ARHP Annual Meeting
Predictors of a Favorable Outcome in Patients with Fibromyalgia: Results From the 1-Year Follow-up
Dong-Jin Park¹, Shin-Seok Lee², Seong-Ho Kim³, Seong-Su Nah⁴, Ji Hyun Lee⁵, Seong-Kyu Kim⁶, Yeon-Ah Lee⁷, Seung-Jae Hong⁷, Hyun-Sook Kim⁸, Hye-Soon Lee⁹, Hyoun Ah Kim¹⁰, Chung-Il Joung¹¹ and Sang-Hyon Kim¹², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ³Department of Internal Medicine,, Inje University Haeundae Paik Hospital, Busan, South Korea, ⁴Rheumatology, Soonchunhyang University, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁸Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ⁹Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁰Ajou University Hospital, Suwon, South Korea, ¹¹Department of Internal Medicine, Konyang university hospital, Daejeon, South Korea, ¹²Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: To determine the outcomes in Korean patients with fibromyalgia (FM) and identify the prognostic factors associated with improvement at 1-year follow-up. Methods: Forty-eight patients…
Abstract Number: 967 • 2012 ACR/ARHP Annual Meeting
Haplotypes of GTP Cyclophydrolase Gene Polymorphisms Are Protective in the Susceptibility of Fibromyalgia Syndrome
Hwajeong Lee¹, Shin-Seok Lee², Seong-Kyu Kim³, Jung-Yoon Choe⁴, Seong-Ho Kim KIM⁵, Seong-Su Nah⁶, Ji Hyun Lee⁷, Seung-Jae Hong⁸, Hyun-Sook Kim⁹, Hye-Soon Lee¹⁰, Hyun Ah Kim¹¹ and Chung-Il Joung¹², ¹Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁵Department of Internal Medicine,, Inje University Haeundae Paik Hospital, Busan, South Korea, ⁶Department of Internal Medicine, Soonchunhyang University, College of Medicine, Cheonan, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ¹⁰Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹²Department of Internal Medicine, Konyang university hospital, Daejeon, South Korea
Background/Purpose: Guanosine triphosphate cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, which is an essential co-factor in nitric oxide (NO) production.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.